Cargando…

Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PURPOSE: The purpose of this study was to develop Korean versions of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (NFOSI-18) and FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 4-item (NTX-4), evaluating their reliabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Maria, Lee, Yumi, Kim, Kidong, Park, Eun Young, Lim, Myong Cheol, Kim, Jung-Sup, Kim, Hee Seung, Kim, Yong-Beom, Kim, Yong-Man, Joo, Jungnam, Park, Sang Yoon, Choi, Chel Hun, Kim, Jae-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333974/
https://www.ncbi.nlm.nih.gov/pubmed/29510610
http://dx.doi.org/10.4143/crt.2017.361
_version_ 1783387647989776384
author Lee, Maria
Lee, Yumi
Kim, Kidong
Park, Eun Young
Lim, Myong Cheol
Kim, Jung-Sup
Kim, Hee Seung
Kim, Yong-Beom
Kim, Yong-Man
Joo, Jungnam
Park, Sang Yoon
Choi, Chel Hun
Kim, Jae-Hoon
author_facet Lee, Maria
Lee, Yumi
Kim, Kidong
Park, Eun Young
Lim, Myong Cheol
Kim, Jung-Sup
Kim, Hee Seung
Kim, Yong-Beom
Kim, Yong-Man
Joo, Jungnam
Park, Sang Yoon
Choi, Chel Hun
Kim, Jae-Hoon
author_sort Lee, Maria
collection PubMed
description PURPOSE: The purpose of this study was to develop Korean versions of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (NFOSI-18) and FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 4-item (NTX-4), evaluating their reliability and reproducibility. MATERIALS AND METHODS: In converting NFOSI-18 and NTX-4, the following steps were performed: forward translation, backward translation, expert review, pretest of preliminary format, and finalization of Korean versions (K-NFOSI-18 and K-NTX-4). Patients were enrolled from six institutions where each had completed chemotherapy for ovarian, tubal, or peritoneal cancer at least 1 month earlier. In addition to demographics obtained by questionnaire, all subjects were assessed via K-NFOSI-18, K-NTX-4, and a Korean version of the EuroQoL-5 Dimension. Internal structural validity and reliability were evaluated using item internal consistency, item discriminant validity, and Cronbach's α. To evaluate test-retest reliability, K-NFOSI-18 and K-NTX-4 were readministered after 7-21 days, and intraclass correlation coefficients (ICCs) were calculated. RESULTS: Of the 250 women enrolled during the 3-month recruitment period, 13 withdrew or did not respond, leaving 237 (94.8%) for the analyses. Mean patient age was 54.3±10.8 years. Re-testing was performed in 190 patients (80.2%). The total K-NFOSI-18 and K-NTX-4 scores were 49 (range, 20 to 72) and 9 (range, 0 to 16), respectively, with high reliability (Cronbach's α=0.84 and 0.89, respectively) and reproducibility (ICC=0.77 and 0.84, respectively) achieved in retesting. CONCLUSION: Both NFOSI-18 and NTX-4 were successfully developed in Korean with minimal modification. Each Korean version showed high internal consistency and reproducibility.
format Online
Article
Text
id pubmed-6333974
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-63339742019-01-22 Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Lee, Maria Lee, Yumi Kim, Kidong Park, Eun Young Lim, Myong Cheol Kim, Jung-Sup Kim, Hee Seung Kim, Yong-Beom Kim, Yong-Man Joo, Jungnam Park, Sang Yoon Choi, Chel Hun Kim, Jae-Hoon Cancer Res Treat Original Article PURPOSE: The purpose of this study was to develop Korean versions of the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy (NCCN-FACT) Ovarian Symptom Index-18 (NFOSI-18) and FACT/Gynecologic Oncology Group (FACT-GOG) Neurotoxicity 4-item (NTX-4), evaluating their reliability and reproducibility. MATERIALS AND METHODS: In converting NFOSI-18 and NTX-4, the following steps were performed: forward translation, backward translation, expert review, pretest of preliminary format, and finalization of Korean versions (K-NFOSI-18 and K-NTX-4). Patients were enrolled from six institutions where each had completed chemotherapy for ovarian, tubal, or peritoneal cancer at least 1 month earlier. In addition to demographics obtained by questionnaire, all subjects were assessed via K-NFOSI-18, K-NTX-4, and a Korean version of the EuroQoL-5 Dimension. Internal structural validity and reliability were evaluated using item internal consistency, item discriminant validity, and Cronbach's α. To evaluate test-retest reliability, K-NFOSI-18 and K-NTX-4 were readministered after 7-21 days, and intraclass correlation coefficients (ICCs) were calculated. RESULTS: Of the 250 women enrolled during the 3-month recruitment period, 13 withdrew or did not respond, leaving 237 (94.8%) for the analyses. Mean patient age was 54.3±10.8 years. Re-testing was performed in 190 patients (80.2%). The total K-NFOSI-18 and K-NTX-4 scores were 49 (range, 20 to 72) and 9 (range, 0 to 16), respectively, with high reliability (Cronbach's α=0.84 and 0.89, respectively) and reproducibility (ICC=0.77 and 0.84, respectively) achieved in retesting. CONCLUSION: Both NFOSI-18 and NTX-4 were successfully developed in Korean with minimal modification. Each Korean version showed high internal consistency and reproducibility. Korean Cancer Association 2019-01 2018-03-07 /pmc/articles/PMC6333974/ /pubmed/29510610 http://dx.doi.org/10.4143/crt.2017.361 Text en Copyright © 2019 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Maria
Lee, Yumi
Kim, Kidong
Park, Eun Young
Lim, Myong Cheol
Kim, Jung-Sup
Kim, Hee Seung
Kim, Yong-Beom
Kim, Yong-Man
Joo, Jungnam
Park, Sang Yoon
Choi, Chel Hun
Kim, Jae-Hoon
Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
title Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
title_full Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
title_fullStr Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
title_full_unstemmed Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
title_short Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
title_sort development and validation of ovarian symptom index-18 and neurotoxicity-4 for korean patients with ovarian, fallopian tube, or primary peritoneal cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333974/
https://www.ncbi.nlm.nih.gov/pubmed/29510610
http://dx.doi.org/10.4143/crt.2017.361
work_keys_str_mv AT leemaria developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT leeyumi developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT kimkidong developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT parkeunyoung developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT limmyongcheol developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT kimjungsup developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT kimheeseung developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT kimyongbeom developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT kimyongman developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT joojungnam developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT parksangyoon developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT choichelhun developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer
AT kimjaehoon developmentandvalidationofovariansymptomindex18andneurotoxicity4forkoreanpatientswithovarianfallopiantubeorprimaryperitonealcancer